|
LBC
|
RT + ve % (95 % CI)
|
HR HC2 + ve % (95 % CI)
|
κ (95 % CI)
|
|---|
|
Normal (Pap I/II)
|
5.4 % (4.2-6.9)
|
5.6 % (4.3-7.1)
|
0.78 (0.69-0.87)
|
|
ASC-US (Pap IIw)
|
21.4 % (12.7-33.8)
|
28.6 % (18.4-41.5)
|
0.62 (0.38-0.86)
|
|
ASC-H, AGC (Pap III)
|
50.0 % (28.0–72.0)
|
50.0 % (28.0–72.0)
|
1 (1.0–1.0)
|
|
LSIL, HSIL (Pap IIID)
|
65.1 % (59.6–70.3)
|
72.1 % (66.8–76.9)
|
0.76 (0.68–0.84)
|
|
HSIL, CIS (Pap IVa)
|
94.7 % (82.7–98.6)
|
100 % (90.8–100)
|
1
|
|
HSIL, CIS, Micro (IVb)
|
100 % (34.2–100)
|
100 % (34.2–100)
|
1
|
|
Micro, Invasive (PapV)
|
100 % (20.6–100)
|
100 % (20.6–100)
|
1
|
|
HSIL+ (≥Pap IVa)
|
95.1 % (83.9–98.7)
|
100 % (91.4–100)
|
1
|
|
AGC+ (≥Pap III)
|
68.0 % (62.9–72.5)
|
74.3 % (69.5–78.6)
|
0.78 (0.70–0.84)
|
|
Overall
|
21.4 % (19.3–23.5)
|
23.4 % (21.3–25.6)
|
0.87 (0.84–0.90)
|
- +ve: positive; −ve: negative; +: and worse
- 95 % CI for HPV prevalence were calculated using the Wilson Score method
